Apelin has in vivo inotropic effects on normal and failing hearts
- PMID: 15364861
- DOI: 10.1161/01.CIR.0000138382.57325.5c
Apelin has in vivo inotropic effects on normal and failing hearts
Abstract
Background: Apelin has been shown ex vivo to be a potent cardiac inotrope. This study was undertaken to evaluate the in vivo effects of apelin on cardiac function in native and ischemic cardiomyopathic rat hearts using a novel combination of a perivascular flow probe and a conductance catheter.
Methods and results: Native rats (n =32) and rats in heart failure 6 weeks after left anterior descending coronary artery ligation (n =22) underwent median sternotomy with placement of a perivascular flow probe around the ascending aorta and a pressure volume conductance catheter into the left ventricle. Compared with sham-operated rats, the ligated rats had significantly decreased baseline Pmax and max dP/dt. Continuous infusion of apelin at a rate of 0.01 microg/min for 20 minutes significantly increased Pmax and max dP/dt compared with infusion of vehicle alone in both native and failing hearts. Apelin infusion increased cardiac contractility, indicated by a significant increase in stroke volume (SV) without a change in left ventricular end diastolic volume (102+/-16% change from initial SV versus 26+/-20% for native animals, and 110+/-30% versus 26+/-11% for ligated animals), as well as an increase in preload recruitable stroke work (180+/-24 mm Hg versus 107+/-9 mm Hg for native animals).
Conclusions: The present study is the first to show that apelin has positive inotropic effects in vivo in both normal rat hearts and rat hearts in failure after myocardial infarction. Apelin may have use as an acute inotropic agent in patients with ischemic heart failure.
Similar articles
-
Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.J Cardiovasc Pharmacol. 1994 Feb;23(2):268-74. J Cardiovasc Pharmacol. 1994. PMID: 7511757
-
Apelin increases contractility in failing cardiac muscle.Eur J Pharmacol. 2006 Dec 28;553(1-3):222-8. doi: 10.1016/j.ejphar.2006.09.034. Epub 2006 Sep 23. Eur J Pharmacol. 2006. PMID: 17055480 Free PMC article.
-
[Hemodynamic effects of various doses of a new inotropic: amrinoma].Arch Inst Cardiol Mex. 1979 Sep-Oct;49(5):961-8. Arch Inst Cardiol Mex. 1979. PMID: 122781 Spanish.
-
[Positive inotropic substances--therapeutic perspectives].Z Kardiol. 1991;80 Suppl 8:57-62. Z Kardiol. 1991. PMID: 1796636 Review. German.
-
New positive inotropic agents.Henry Ford Hosp Med J. 1986;34(3):188-92. Henry Ford Hosp Med J. 1986. PMID: 3542907 Review. No abstract available.
Cited by
-
Endogenous regulation of cardiovascular function by apelin-APJ.Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1904-13. doi: 10.1152/ajpheart.00686.2009. Epub 2009 Sep 18. Am J Physiol Heart Circ Physiol. 2009. PMID: 19767528 Free PMC article.
-
Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.ACS Med Chem Lett. 2021 Oct 22;12(11):1766-1772. doi: 10.1021/acsmedchemlett.1c00385. eCollection 2021 Nov 11. ACS Med Chem Lett. 2021. PMID: 34795866 Free PMC article.
-
Apelin/APJ-Manipulated CaMKK/AMPK/GSK3β Signaling Works as an Endogenous Counterinjury Mechanism in Promoting the Vitality of Random-Pattern Skin Flaps.Oxid Med Cell Longev. 2021 Jan 25;2021:8836058. doi: 10.1155/2021/8836058. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 33574981 Free PMC article.
-
Early Administration of Apelin Could Prevent Heart Failure Following Myocardial Injury; A Systematic Review and Meta-Analysis.Arch Acad Emerg Med. 2024 Sep 5;13(1):e4. doi: 10.22037/aaem.v13i1.2414. eCollection 2025. Arch Acad Emerg Med. 2024. PMID: 40093029 Free PMC article. Review.
-
Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction.J Biomed Res. 2012 Nov;26(6):400-9. doi: 10.7555/JBR.26.20120052. Epub 2012 Oct 20. J Biomed Res. 2012. PMID: 23554778 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases